Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Additionally we are shipping UBE2C Proteins (27) and UBE2C Kits (11) and many more products for this protein.
Showing 10 out of 142 products:
Human Monoclonal UBE2C Primary Antibody for IF, IHC (p) - ABIN564800
Jiang, Huang, Lu, Luo, Hu, Liu, Chen, Han: Expression of ubiquitin-conjugating enzyme E2C/UbcH10 in astrocytic tumors. in Brain research 2008
Show all 8 Pubmed References
Human Polyclonal UBE2C Primary Antibody for ELISA - ABIN249620
Townsley, Aristarkhov, Beck, Hershko, Ruderman: Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. in Proceedings of the National Academy of Sciences of the United States of America 1997
A role was identified for UBE2C as a marker of the androgen signaling pathway in prostate cancer.
Data suggest that the activity of AURKA (show AURKA Antibodies) might be regulated by UBE2C through regulating the activity of anaphasepromoting complex. UBE2C may be a new marker in the diagnosis of gastric cancer and may be a potential therapeutic target for the treatment of gastric adenocarcinoma.
High UBCH10 expression is associated with bortezomib-resistance in multiple myeloma.
the expression of UbcH10 in colorectal cancer samples as compared with healthy tissue sample from the same patient according to age at surgery, was examined.
UbcH10 may promote gastric cancer growth.
Identification of UBE2C as a target of wild-type and GOF mutant p53 (show TP53 Antibodies) further highlights the contribution of p53 (show TP53 Antibodies) in regulation of spindle assembly checkpoint
The anaphase-promoting complex/cyclosome C activity in human cells is tuned by the combinatorial use of three E2 ubiquitin-conjugating enzymes, namely UBE2C, UBE2S (show UBE2S Antibodies), and UBE2D.
Study shows an overexpression of UbcH10 mRNA and protein in the vast majority of colorectal cancer (CRC (show CALR Antibodies)) patients analyzed and indicates that UbcH10 expression regulates CRC (show CALR Antibodies) growth.
the present study showed that miR (show MLXIP Antibodies)-196a promoted cell proliferation by targeting UBE2C in breast cancer. Thus, miR (show MLXIP Antibodies)-196a may be a potential oncogene (show RAB1A Antibodies) in breast cancer and a promising therapeutic target in breast cancer treatment.
UBE2C could regulate phospho-ERK1/2 (show MAPK1/3 Antibodies) level.
alongside their canonical function in protein degradation, Ube2C and -S also control the extrusion of the first polar body.
UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer.
results identify UbcH10 as a prominent protooncogene that causes whole chromosome instability and tumor formation over a wide gradient of overexpression levels
The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. This enzyme is required for the destruction of mitotic cyclins and for cell cycle progression. Multiple transcript variants encoding different isoforms have been found for this gene.
ubiquitin-conjugating enzyme E2C
, ubiquitin carrier protein C
, ubiquitin-protein ligase C
, cyclin-selective ubiquitin carrier protein
, mitotic-specific ubiquitin-conjugating enzyme
, ubiquitin-conjugating enzyme E2 C